Lupin is known to be a best known company in the pharma industry. With high market capital of around 76000 crore, it is an investor friendly company with CRR of 46% as a good pay master to its share holding paying good amount of dividend regular.
An able management maintaining the input cost controlling the raw material cost, it enjoys profit generating efficiency level of 35% with the debt equity ratio of mere 0.01 and rising reserves of around 8930 crore. Its price to earning almost matches the other industry players.
At current valuations, stock is worth 1500 or so for the investors who can eye this stock for med to long term.